Muutke küpsiste eelistusi

E-raamat: AIDS Clinical Review 2000/2001

Edited by (San Francisco General Hospital, California, USA)
  • Formaat: 336 pages
  • Sari: Aids Clinical Review
  • Ilmumisaeg: 01-Sep-2000
  • Kirjastus: CRC Press Inc
  • Keel: eng
  • ISBN-13: 9781420002652
  • Formaat - PDF+DRM
  • Hind: 64,99 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Raamatukogudele
  • Formaat: 336 pages
  • Sari: Aids Clinical Review
  • Ilmumisaeg: 01-Sep-2000
  • Kirjastus: CRC Press Inc
  • Keel: eng
  • ISBN-13: 9781420002652

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

The latest in the crucial series documenting scientific discoveries at the forefront of HIV and AIDS research! This volume updates the most important and controversial issues facing physicians, nurses, microbiologists, pharmacists, and epidemiologists who deal directly with patients suffering from HIV and AIDS, focusing on specific areas in which important new advances have occurred in diagnosis, therapy, and prevention of infection and related complications. Outlines new disease management strategies being tested in prospective clinical trials and observational studies! Combining elements of virology, epidemiology, immunology, oncology, endocrinology, neurology, psychiatry, and the behavioral sciences, AIDS Clinical Review 2000/2001

clarifies substantive advancements in vaccine development, realistically assessing potential efficacy and limitations

explores short-term antiretroviral therapy for dramatically reducing the rate of vertical transmission from mother to child

evaluates the efficacy of antiretroviral prophylaxis for workers who experience high-risk exposure to HIV-infected blood

discusses preservation of HIV specific immunity when antiretroviral therapy is initiated early in the course of acute infection

considers complex drug interactions that occur when drugs are used in combination

highlights cytokine and other immune-based therapies

suggests chronic hepatitis may ultimately be more fatal than HIV for coinfected patients

and more! Including results recently presented at scientific meetings but not yet published in peer-reviewed journals, AIDS Clinical Review 2000/2001 is essential reading for infectious disease specialists, epidemiologists, virologists, immunologists, pharmacologists, microbiologists, hematologists, hepatologists, oncologists, neurologists, medical students in these disciplines, and all medical professionals involved in both AIDS research and clinical practice.

Arvustused

" a very well organized set of reviews, providing much new information for the researcher. It is a highly recommended series that all medical and academic libraries should subscribe to and have available for their users. "-AIDS Book Review Journal

Praise for the previous edition" focuses on new developments, including epidemiology as well as pathogenic aspects, and current opinions based on the latest publicationsprovides comprehensive bibliographies....not just another textbook on AIDS. "-Infection

Preface iii Contributors xi Human Immunodeficiency Virus Prevention: Applying the Lessons Learned 1(22) Thomas J. Coates Anke A. Ehrhardt David D. Celentano Intervention Strategies: Levels of Interventions 4(9) Where are the Needs? 13(3) What Can We Recommend Now? 16(1) Conclusion 17(6) References 17(6) Novel Strategies Toward the Development of an Effective Vaccine to Prevent Human Immunodeficiency Virus Infection or Acquired Immunodeficiency Virus 23(40) Barbara Ensoli Aurelio Cafaro How AIDS Vaccine Strategies Have Evolved from Sterilizing Immunity to the Control of Infection 25(4) Live Attenuated Vaccines: Concepts to Learn 29(1) Novel Strategies 30(13) Conclusions and Perspectives 43(20) References 46(17) Pediatric Human Immunodeficiency Virus Type 1 Infection: Updates on Prevention and Management 63(22) Ann J. Melvin Lisa M. Frenkel Introduction 65(1) Maternal and Obstetrical Factors Associated with Perinatal HIV-1 Transmission 66(9) Antiretroviral Therapy for HIV-1-Infected Children 75(2) Summary 77(8) References 77(8) Risk of Human Immunodeficiency Virus Infection in Health Care Workers 85(16) Rita Fahrner Introduction 87(1) Anecdotal Case Reports of Occupational HIV Infection 88(3) Prospective Cohort Studies 91(1) Prevention 92(2) Management of Occupational Exposure 94(2) HIV-Infected Health Care Workers: Risks to Patients 96(1) Conclusion 97(4) References 98(3) Can Immune Responses to Human Immunodeficiency Virus Be Preserved, Enhanced, or Restored? 101(14) Bruce D. Walker Introduction 103(1) Components of Protective Immunity in HIV Infection 104(2) Why Does the Immune System Fail to Control HIV? 106(1) Effects of Highly Active Antiretroviral Therapy (HAART) on HIV-Specific Immune Responses 106(1) Rebuilding the Immune System in Chronic HIV Infection 107(1) Critical Need for Immunotherapy plus HAART in Augmenting Immunity to HIV 108(1) Approaches to Immune Enhancement in HIV Infection 109(1) Conclusions and Future Directions 110(5) References 111(4) Reconstitution of Immunity Against Opportunistic Infections in the Era of Potent Antiretroviral Therapy 115(24) Judith A. Aberg Introduction 117(1) PCP 118(5) MAC 123(3) CMV 126(3) Toxoplasmosis 129(1) Systemic Mycoses 130(1) Summary 130(9) References 131(8) Salvage Therapy for Patients Failing their Current Antiretroviral Regimen 139(54) Mary A. Albrecht Background 141(3) Defining Virologic Failure 144(1) When to Switch Therapy 145(1) Devising Salvage Therapy 146(4) Salvage Therapy in Patients Failing PI-Containing Regimens: Clinical Trial Results 150(9) Role of Intensification Strategies 159(2) Predictors of Treatment Response 161(8) Role of Genotypic and Phenotypic Resistance Assays in Devising Salvage Therapy 169(7) Structured Treatment Interruptions 176(1) Multidrug Rescue Regimens 177(2) Conclusions 179(14) References 180(13) Drug Interactions of Antiretroviral Agents 193(36) Bradley W. Kosel Francesca Aweeka Overview 195(2) Interpretation of Drug Concentrations 197(1) Interaction Types 197(1) Inhibitor and/or Inducer 198(2) Nucleoside Reverse Transcriptase Inhibitors 200(4) PI Combinations 204(5) NNRTI and PI Combinations 209(5) Management of Non-ARV Drug Interactions 214(6) Conclusion 220(9) References 221(8) Rationale for Immune-Based Therapies for Human Immunodeficiency Virus Type 1 Infection 229(34) Michael M. Lederman Hernan Valdez Rationale for Immune-Based Therapies 231(2) Host-Directed Therapies 233(4) Cytokines and Growth Factors 237(5) Enhancement of HIV-1 Specific Immune Responses 242(7) Conclusion 249(14) References 250(13) Human Immunodeficiency Virus and Hepatitis B and C Coinfection: Pathogenic Interactions, Natural History, and Therapy 263(44) Arthur Y. Kim Raymond T. Chung Bruce Polsky Introduction 265(1) HIV and HBV 266(4) HIV and HCV 270(16) Conclusion 286(21) References 286(21) Index 307
Paul A. Volberding